Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1Phase 2/3 1

Status

Recruiting 3Completed 2Terminated 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

NET 6Endocrine 6Gastrointestinal 1

Conditions

Neuroendocrine Tumors 35Carcinoma, Neuroendocrine 10Carcinoid Tumor 10Neoplasms 6Adenoma, Islet Cell 6Carcinoma, Renal Cell 5Carcinoma, Islet Cell 5Somatostatinoma 4Pheochromocytoma 4Insulinoma 4Glucagonoma 4Carcinoma, Medullary 4Paraganglioma 3Neoplasm Metastasis 3Gastrinoma 3Carcinoma 3Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Neuroectodermal Tumors, Primitive 2Liver Neoplasms 2Head and Neck Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Adenocarcinoma, Follicular 2von Hippel-Lindau Disease 1Zollinger-Ellison Syndrome 1Tuberous Sclerosis 1

Interventions

Everolimus 6Sunitinib 3Octreotide 3cabozantinib 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Leucovorin 2Injections 2Fluorouracil 2Capecitabine 2Bevacizumab 2recombinant interferon alpha 2b-like protein 1pentetreotide 1pasireotide 1motesanib diphosphate 1lanreotide 1ibrutinib 1ganitumab 1gallium Ga 68 dotatate 1fludarabine phosphate 1belzutifan 1batifiban 1atezolizumab 1abemaciclib 1X-Rays 1Thalidomide 1Temozolomide 1Streptozocin 1Sorafenib 1Phantoms, Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × Everolimus × Endocrine × Clear all
NCT06943755 2026-04-17

STELLAR-311

Exelixis

Phase 2/3 Recruiting
440 enrolled
EndocrineNET

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT05477576 2026-03-30

ACTION-1

RayzeBio, Inc.

Phase 3 Recruiting
338 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT06472388 2024-06-25

EVENET

AC Camargo Cancer Center

Phase 2 Recruiting
100 enrolled
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors, Disease Progression

NCT01374451 2016-12-20

COOPERATE-2

Novartis

Phase 2 Terminated
160 enrolled 17 charts
EndocrineNET

Adenoma, Islet Cell, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT00804336 2016-10-19

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 1 Completed
22 enrolled
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT00942682 2014-04-29

Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 1 Completed
21 enrolled
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡